RayKnowChina Research Map
Shortlist0

RecruitingStomach cancerN/A

Registered title, quoted from ClinicalTrials.gov

A Prospective Study on Esophagogastrostomy by an Innovative Surgical Technique

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Huashan Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorHuashan Hospital复旦大学附属华山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06300879, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Pathologically confirmed as adenocarcinoma;

    Inclusion criterion 2

  3. Preoperative assessment indicating cT4b or Bulky lymph nodes enlargement or distant lymph nodes metastasis;

    Exclusion criterion 1

  4. Preoperative ECOG (Eastern Cooperative Oncology Group) score of 0/1.

    Inclusion criterion 9

  5. History of other malignant tumors in the past 5 years;

    Exclusion criterion 6

  6. Pregnant or lactating women;

    Exclusion criterion 2

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; blood tests: counts, liver and kidney function; scans and measurable lesions.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06300879, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age between 18 and 75 years old;
  • Pathologically confirmed as adenocarcinoma;
  • Primary tumor located in the upper 1/3 of the stomach or the gastroesophageal junction (Siewert II or III);
  • If it is adenocarcinoma of the upper 1/3 of the stomach, cT1N0M0 should be met.
  • For gastroesophageal junction adenocarcinoma, cT1-2N0M0 should be met, and clinical judgment should indicate no distant lymph node metastasis around the stomach.
  • Bilateral resection margins should be greater than 2 cm, and more than half of the residual stomach should be preserved.
  • No history of upper abdominal surgery (excluding laparoscopic cholecystectomy).
  • No preoperative comprehensive treatments such as chemotherapy, radiotherapy, targeted therapy, immunotherapy, etc.
  • Preoperative ECOG (Eastern Cooperative Oncology Group) score of 0/1.
  • Preoperative ASA (American Society of Anesthesiologists) score I-III.
  • Good function of important organs.
  • Signed informed consent.

Exclusion Criteria:

  • Preoperative assessment indicating cT4b or Bulky lymph nodes enlargement or distant lymph nodes metastasis;
  • Pregnant or lactating women;
  • Patients with severe mental illness;
  • Preoperative temperature ≥38°C or infectious diseases requiring systemic treatment;
  • Severe respiratory diseases, with FEV1 < 50% of predicted value;
  • History of other malignant tumors in the past 5 years;
  • Severe liver or kidney dysfunction;
  • Unstable angina or myocardial infarction within the last 6 months;
  • History of stroke or cerebral hemorrhage within the last 6 months (excluding old infarcts);
  • Systemic use of glucocorticoids within the last 1 month;
  • Emergency surgery required due to complications of gastric cancer (bleeding, perforation, obstruction);
  • Patient has participated in or is currently participating in other clinical trials (within the last 6 months).

Quoted from ClinicalTrials.gov, NCT06300879, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06300879, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06300879